Shechtman Yelena, Shalata Walid, Khoury Rasha, Mahajna Ayed, Weller Boaz, Agbarya Abed
Departments of Oncology.
The Legacy Heritage Oncology Center and Dr Larry Norton Institute, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel.
J Immunother. 2021 Sep 1;44(7):243-247. doi: 10.1097/CJI.0000000000000362.
The immune checkpoint inhibitors have improved the standards of care in cancer treatment and have dramatically improved patient prognoses. These new antibodies turned to be an integral part of the standard of care for metastatic small-cell lung cancer. Platinum-based chemotherapy combined with checkpoint inhibitors, resulted in statistically significant improvement of progression free survival and overall survival. Immune checkpoint inhibitors immune-related adverse events have been observed and reported as a consequence of administering these innovative treatment drugs. Neurological immune-related adverse events are rare complications; however, they can be potentially fatal, particularly encephalitis. This report describes a 66-year-old female who received Durvalumab for metastatic small-cell lung cancer. Following 3 cycles of treatment, she developed encephalitis.
免疫检查点抑制剂提高了癌症治疗的护理标准，并显著改善了患者的预后。这些新型抗体已成为转移性小细胞肺癌护理标准的一个组成部分。铂类化疗联合检查点抑制剂，在无进展生存期和总生存期方面有统计学意义的显著改善。作为使用这些创新治疗药物的结果，免疫检查点抑制剂相关的免疫不良事件已被观察和报道。神经系统免疫相关不良事件是罕见的并发症；然而，它们可能是致命的，尤其是脑炎。本报告描述了一名66岁女性，她因转移性小细胞肺癌接受度伐利尤单抗治疗。在3个周期的治疗后，她患上了脑炎。
